title: [Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension].
abstract: OBJECTIVE
  This study was undertaken to compare the ocular haemodynamic effects of Combigan(®) versus placebo in patients with ocular hypertension (OHT).
  
  
  METHODS
  Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan(®) and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging(CDI) ultrasound, concurrently with intraocular pressure (IOP).
  
  
  RESULTS
  Combigan(®) significantly reduced IOP after 3 months of treatment (P = 0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P = 0.007).
  
  
  CONCLUSIONS
  Patients treated for 3 months with Combigan(®) showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP.
authors: Servicio de Oftalmología, Unidad de Glaucoma, IRYCIS, Hospital Ramón y Cajal, Madrid, España. beapuertoh@hotmail.com
authors: B
authors: B
authors: Puerto-Hernández
authors: G
authors: G
authors: Rebolleda
authors: J L
authors: JL
authors: García-Pérez
authors: F J
authors: FJ
authors: Muñoz-Negrete
authors: C
authors: C
authors: González-Gordaliza
mesh_terms: D000368:Aged; D000068599:Brimonidine Tartrate, Timolol Maleate Drug Combination; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D017078:Laser-Doppler Flowmetry; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009880:Ophthalmic Artery / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011810:Quinoxalines / Q000494:pharmacology / Q000627:therapeutic use*; D012039:Regional Blood Flow / Q000187:drug effects; D012171:Retinal Vessels / Q000503:physiopathology; D013999:Timolol / Q000494:pharmacology / Q000627:therapeutic use*; D018615:Ultrasonography, Doppler, Color; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000068599:Brimonidine Tartrate, Timolol Maleate Drug Combination; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D013999:Timolol